
Jan 14 (Reuters) - BridgeBio Pharma Inc BBIO.O:
BRIDGEBIO CONTINUES LONG TERM DEBT MANAGEMENT STRATEGY AND ANNOUNCES PROPOSED OFFERING OF CONVERTIBLE SENIOR NOTES DUE 2033 TO PREFUND REPAYMENT OF CONVERTIBLE SENIOR NOTES DUE 2027
BRIDGEBIO PHARMA INC - TO OFFER $550 MILLION CONVERTIBLE SENIOR NOTES DUE 2033
BRIDGEBIO PHARMA INC - PROCEEDS TO REPURCHASE OR REPAY 2027 NOTES